U.S. Court in DC Sides with Drug Maker in Medicaid Rebate Reclassification Suit
- March 27, 2020
The U.S. District Court for the District of Columbia granted summary judgment March 23 to drug maker STI Pharma, LLC, finding its drug Sulfatrim Pediatric Suspension should retroactively be classified as a noninnovator multiple source drug under the Medicaid Drug Rebate Program (MDRP).
ARTICLE TAGS
You must be logged in to access this content.